Remote Patient Monitoring Market - Strategic Insights and Forecasts (2026-2031)

The Remote Patient Monitoring Market is set to reach USD 39.1 billion in 2031, growing at a CAGR of approximately 21.6% between 2026 and 2031, from USD 14.7 billion in 2026.

Market Overview

Remote patient monitoring connects medical measurements collected outside conventional clinical encounters with teams responsible for reviewing and acting on those measurements. The market includes connected devices, attributable software and monitoring services used within clinically managed programs. Typical measurements include blood pressure, glucose, oxygen saturation, cardiac activity and body temperature. A device becomes commercially relevant to RPM when its data can enter a defined care workflow; connectivity alone does not establish clinical use. Consequently, standalone consumer wellness products and ordinary home diagnostic purchases should not automatically be counted as RPM revenue. The study retains the supplied headline estimate of USD 14.7 billion in 2026 and USD 39.1 billion in 2031. These endpoints imply approximately 21.6% annual growth over five years. Their commercial interpretation depends on consistent treatment of hardware, software and services across the forecast period.

The principal commercial opportunity lies in converting intermittent measurement into a repeatable monitoring relationship. Providers need onboarding, device logistics, patient support, alert review and integration with existing records. Vendors that support these functions can compete for recurring contracts rather than relying only on hardware replacement. Wearable sensors can extend the frequency of observation, while connected cuffs and scales remain useful where periodic measurements fit the clinical purpose. Greater measurement frequency also creates operational costs: teams must distinguish actionable changes from missing readings, technical errors and low-priority notifications. Growth therefore depends on the economics of the full monitoring workflow. Contracts that specify clinical responsibilities, service levels and escalation ownership are more likely to support scalable deployment than arrangements centered solely on device distribution.

• Within digital health, RPM provides an ongoing data relationship between patients and care teams. Its addressable revenue should be separated from unrelated video consultations and general healthcare IT expenditure.

• The use of healthcare artificial intelligence can support prioritization and workflow assistance. Commercial value depends on validation, oversight and integration rather than the presence of an AI label.

• Bundled contracts require careful revenue allocation. Device receipts, software fees and outsourced monitoring payments must be counted once within the market boundary; provider reimbursement cannot simply be added to supplier revenue when it finances the same service.

Market Drivers

Rising Burden of Chronic Diseases and Demand for Continuous Care

Chronic disease management creates repeated demand for measurements between appointments. Hypertension, diabetes and heart failure involve treatment decisions informed by changes over time, making them relevant use cases for connected monitoring. The business opportunity is strongest where regular data review can be embedded into an existing care pathway and funded through a sustainable contract or reimbursement mechanism. Disease prevalence establishes the potential patient pool, but it does not equal paying demand: diagnosis, treatment access, clinical eligibility, patient consent and provider capacity determine how many people can enter an RPM program. This distinction matters particularly in countries where connected devices are affordable but staff time and service funding are constrained. Vendors must therefore pair clinical relevance with accessible onboarding, dependable support and a credible operating model. Expanding a program without adequate review capacity can increase the volume of unaddressed alerts instead of improving the usefulness of monitoring.

• WHO estimated that 1.4 billion adults aged 30–79 had hypertension in 2024. This demonstrates a substantial clinical need; only a portion of that population can reasonably be treated as a near-term commercial RPM opportunity.

• The IDF Diabetes Atlas 2025 estimates that 589 million adults aged 20–79 had diabetes in 2024, with 853 million projected for 2050. This supports long-term demand for continuous glucose monitoring and associated clinical data services, without implying that all CGM sales belong within RPM.

• Procurement increasingly requires evidence of manageable staff workload, sustained patient participation and clear responsibility for abnormal readings. These requirements favor solutions designed around a specific care pathway.

• Reimbursement supports uptake where programs meet eligibility, documentation and service requirements. Payment availability alone does not establish profitability after device supply, connectivity, staffing and patient-support costs.

Major Segment Analysis

Hypertension Monitoring — By Application

Hypertension sits within Chronic Disease Management in the existing application segmentation. The scenario estimates attributable RPM revenue of USD 1.44 billion in 2026, rising to USD 3.27 billion in 2031. This represents a 17.8% CAGR over five years. Against the supplied overall market totals, its share moves from 9.8% in 2026 to 8.4% in 2031. Revenue therefore expands substantially while its relative contribution declines because the overall market forecast grows faster. This is a selected application deep dive, rather than a claim that hypertension is the largest RPM category. The calculation concerns clinician-managed hypertension programs and their attributable technology and monitoring-service revenue. It does not measure the standalone blood-pressure monitor device market, and it does not include all healthcare expenditure incurred by people who have hypertension. The figures are estimates; underlying enrollment and revenue assumptions are not independently measured market observations.

The base-year calculation assumes 4.0 million annual-equivalent monitored patients and USD 360 in attributable annual revenue per patient, giving USD 1.44 billion. The forecast assumes 8.175 million annual-equivalent monitored patients and USD 400 per patient in 2031, giving USD 3.27 billion. Annual-equivalent patients are monitored patient-months divided by twelve, so a person monitored for only three months contributes one quarter of an annual equivalent. This treatment avoids valuing every enrolled person as a full year of revenue. The implied patient-equivalent CAGR is approximately 15.4%, while revenue per patient rises about 2.1% annually. Together these assumptions produce the segment forecast. The population statistics establish clinical context, but they do not validate these commercial conversion assumptions. Enrollment, retention, net contract prices and the allocation of bundled fees are the main variables requiring further evidence.

• Connected blood-pressure measurements can support longitudinal review and treatment follow-up. Commercial differentiation depends on dependable transmission, usable patient instructions and defined escalation processes, alongside measurement accuracy.

• Multimorbidity requires a consistent primary-application allocation. A patient with both diabetes and hypertension must not generate duplicate recognition of the same bundled subscription in two application segments.

• The revenue boundary includes attributable devices, software and contracted monitoring services once. Reimbursement receipts and vendor payments financing the same service are not additive.

• If enrollment or revenue per patient is 20% below the base assumption, segment revenue falls 20% when the other input is held constant. Both inputs falling 20% would reduce revenue 36%, illustrating the sensitivity of the estimate.

Homecare Settings

The existing end-user segmentation includes hospitals and clinics, ambulatory care centers, homecare settings and others. Homecare settings remain relevant because patients can collect measurements during ordinary daily routines, reducing reliance on visits solely for data collection. However, the monitoring location and the contracting customer must be distinguished. A hospital-operated program delivered in a patient’s home should be allocated consistently under the chosen customer convention; it should not also be counted as a separate homecare purchase. Dedicated homecare organizations can use RPM to coordinate follow-up and identify changes that require review, but the commercial model must absorb installation, connectivity support, device recovery and patient training. Suppliers that simplify these practical tasks can improve retention and reduce service costs. This supports the homecare opportunity without assigning an unsupported market share or asserting that it is the fastest-growing end-user category.

• For homecare operators, ease of use and technical support influence whether patients continue to submit readings after initial enrollment.

• Interoperability can reduce duplicate entry and make monitoring data available within established clinical workflows, although implementation and maintenance remain important purchasing costs.

• The distinction between remote physiological monitoring and remote therapy management should be maintained when evaluating platforms serving specialized home treatments.

Regional Analysis

North America: the US

The United States offers an established reimbursement environment for remote physiological monitoring, making it an important commercial reference point. In 2026, CPT 99445 addresses device monitoring with 2–15 days of recordings or alerts within the applicable period, while CPT 99470 addresses shorter treatment-management time beginning at ten minutes. These options can support clinically appropriate shorter episodes, but they do not create unrestricted additional billing: alternative duration codes must be used according to their requirements. Providers still need patient consent, compliant devices, documentation and the capacity to review data. Vendors therefore compete on their ability to support reliable clinical and administrative workflows. Market growth should be assessed through actual adoption, collected revenue and retention rather than multiplying a published reimbursement rate by the entire eligible population.

• Health-system buyers may prefer integration with existing records and centralized review processes, while smaller practices may place greater weight on onboarding support and outsourced operational services.

• Connectivity barriers, patient participation and staffing costs can limit deployment even where reimbursement exists. These variables affect both contract renewal and realized revenue per monitored patient.

• North America is discussed as a commercially important region; no numerical regional leadership claim is made without a reconciled geographic model.

Company Profiles

Abbott Laboratories participates in connected chronic care through glucose monitoring and cardiovascular technologies. Its commercial relevance to RPM depends on the specific connected product, the associated clinical workflow and the attributable revenue boundary. A diversified supplier’s total medical-device revenue should not be treated as RPM sales. The distinction is particularly important when sensors are used for patient self-management without an ongoing clinician-supervised monitoring service.

Abbott’s February 2026 FDA approval for the CardioMEMS HERO reader illustrates the role of usability in a recurring monitoring relationship. The reader supports collection and transmission of pulmonary artery pressure measurements for patients with an implanted CardioMEMS sensor. For suppliers, improving the routine measurement experience can support continued participation and strengthen the broader connected-care offering. This product development establishes relevant market activity; it does not independently establish Abbott’s share of the overall RPM market.

Key Developments

• October 2026: Teladoc Health announced SoloVitals and SoloScribe within its Solo platform. SoloScribe was generally available; SoloVitals was in private preview, with general release expected in December 2026. These hospital workflow capabilities illustrate connected-care platform development rather than a completed rollout of home RPM.

• September 2026: Peerbridge Health announced FDA 510(k) clearance for Cor MDx, an ambulatory wearable recording continuous multichannel ECG for up to 14 days.

• August 2026: Philips announced collaborations with Blue Spark Technologies, Caretaker Medical, Cuviva, LifeSignals, Respiree and smartQare to expand its wearable and out-of-hospital monitoring ecosystem.

• June 2026: Fresenius Medical Care launched kinexus globally to connect home dialysis therapy monitoring and operational workflows. This is an adjacent remote therapy platform development; its full revenue is not automatically included in physiological RPM.

• February 2026: Abbott received FDA approval for its CardioMEMS HERO reader, an updated patient system supporting remote pulmonary artery pressure monitoring.

Remote Patient Monitoring Market Scope: